Sutro Biopharma logo
Sutro Biopharma STRO
$ 19.54 0.34%
report update icon

Quarterly report 2026-Q2
added 08-12-2026

Sutro Biopharma Financial Statements 2025-2011 | STRO

Annual Financial Statements Sutro Biopharma

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

181 M 165 M 197 M 238 M 411 M 723 M 223 M 61.5 M - - - - - - -

Shares

8.5 M 7.74 M 60.2 M 50.7 M 46.1 M 32.6 M 23 M 5.76 M - - - - - - -

Historical Prices

21.3 21.3 3.27 4.69 8.92 22.2 9.73 8.8 - - - - - - -

Net Income

-191 M -227 M -107 M -119 M -106 M -32.1 M -119 M -35.3 M -19.7 M 1.7 M - - - - -

Revenue

102 M 62 M 154 M 67.8 M 61.9 M 42.7 M 42.7 M 38.4 M 51.7 M 59.7 M - - - - -

Operating Income

-158 M -238 M -89.3 M -129 M -98.5 M -71.1 M -55.5 M -37.2 M -19.3 M 1.36 M - - - - -

Interest Expense

- - - - - - - 1.62 M 612 K - - - - - -

EBITDA

-151 M -231 M -82.5 M -123 M -93.7 M -66.8 M -50.7 M -32.7 M -14.3 M 7.03 M - - - - -

Operating Expenses

261 M 300 M 243 M 197 M 160 M 114 M 98.2 M 75.6 M - - - - - - -

General and Administrative Expenses

41 M 48.5 M 62.6 M 59.5 M 56 M 36.8 M 32.6 M 21.4 M 16.4 M 14.8 M - - - - -

All numbers in USD currency

Quarterly Income Statement Sutro Biopharma

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

8.51 M 13.1 M - 84.9 M 84.6 M 83.1 M 82.5 M 82 M 81.2 M 61.5 M 61 M 60.6 M 60.3 M 58.7 M 57.5 M 52.3 M 47 M 46.5 M 46.3 M 46.2 M 46.1 M 45.9 M 45.8 M 36.9 M 29.9 M 23.2 M 23.1 M 22.9 M 22.9 M 22.9 M 22.8 M 482 K 478 K 468 K 465 K 452 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-76 M -38.5 M - -56.9 M -11.5 M -76 M - -48.8 M -48 M -58.2 M - -49.3 M -38.5 M -50 M - -19.5 M -26 M -39.1 M - -30.9 M -6.15 M -30.4 M -59.5 M 17.1 M 29.9 M -19.6 M -14.8 M -12.9 M -13.8 M -14.2 M -1.49 M -10.2 M -11.5 M -12 M -15.3 M -1.42 M -1.81 M -1.11 M - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

63.7 M 14.5 M - 9.69 M 63.7 M 17.4 M - 8.52 M 25.7 M 13 M - 16.9 M 10.4 M 12.7 M - 25.1 M 28.1 M 5.9 M - 8.52 M 28 M 14.7 M 8.28 M 17.8 M 9.47 M 7.15 M 11.3 M 12.3 M 10.5 M 8.63 M 19.1 M 7.84 M 5.7 M 5.79 M 4.04 M 17.5 M 15.4 M 14.8 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-3.34 M -29.7 M - -48.5 M -3.34 M -68.5 M - -67.9 M -48.7 M -56.6 M - -44 M -46.2 M -42.2 M - -21.2 M -19.4 M -39.1 M - -34.7 M -9.8 M -19 M - -10.6 M -16.4 M -19.2 M - -12.7 M -13.7 M -14.3 M - -10.2 M -12.1 M -11.7 M - -1.06 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -1.16 M - 415 K - - - 235 K - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-3.34 M -28.4 M - - - -66.6 M - - - -54.8 M - - - -40.6 M - -17 M -16.7 M -37.8 M - -31.1 M -7.39 M -17.7 M - -7.49 M -14.3 M -18.1 M - -9.18 M -11.4 M -13.1 M - -6.75 M -9.8 M -10.5 M - 2.73 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

67.1 M 44.2 M - 58.2 M 67.1 M 85.9 M - 76.4 M 74.4 M 69.6 M - 60.9 M 56.6 M 54.9 M - 46.4 M 47.5 M 45 M - 43.2 M 37.9 M 33.7 M - 28.4 M 25.9 M 26.3 M - 25 M 24.2 M 22.9 M - 18 M 17.8 M 17.5 M - 18.6 M - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

10.3 M 7.58 M - 8.74 M 10.3 M 13.3 M - 14.3 M 12.4 M 12.7 M - 15.3 M 15 M 15.5 M - 14.6 M 15.1 M 15 M - 16.6 M 12.5 M 11.1 M - 9.08 M 8.64 M 8.71 M - 8.12 M 8.07 M 7.72 M - 5.35 M 4.04 M 4.41 M - 4.9 M - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Sutro Biopharma STRO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Sutro Biopharma plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Immunome Immunome
IMNM
$ 27.05 1.08 % $ 2.36 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 1.36 3.76 % $ 1.33 M canadaCanada
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
$ 1.42 0.35 % $ 66.6 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 5.19 0.68 % $ 994 M canadaCanada
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 55.86 0.4 % $ 8.94 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 8.85 0.68 % $ 3.16 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 27.94 0.57 % $ 4.7 B usaUSA
Jaguar Health Jaguar Health
JAGX
$ 0.45 1.58 % $ 1.05 M usaUSA
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 243.0 0.22 % $ 14.8 B irlandaIrlanda
Johnson & Johnson Johnson & Johnson
JNJ
$ 268.1 1.17 % $ 645 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 8.3 2.17 % $ 362 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 77.91 0.28 % $ 5.78 B usaUSA
Kodiak Sciences Kodiak Sciences
KOD
$ 34.81 0.13 % $ 1.85 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 1.75 1.13 % $ 19.1 K usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 11.27 1.89 % $ 419 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 119.91 2.15 % $ 10.1 B usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 1.14 4.61 % $ 262 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 280.29 0.98 % $ 5.42 B usaUSA
Longeveron Longeveron
LGVN
$ 6.64 3.5 % $ 117 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 121.89 0.03 % $ 1.01 T usaUSA
Adagene Adagene
ADAG
$ 3.58 0.14 % $ 211 M chinaChina
Lipocine Lipocine
LPCN
$ 2.4 1.24 % $ 13.1 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 67.92 0.5 % $ 5.85 B usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
$ 3.87 0.91 % $ 322 M usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 2.22 0.89 % $ 806 M usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 6.98 6.91 % $ 4.67 M usaUSA
Mustang Bio Mustang Bio
MBIO
$ 0.54 3.28 % $ 2.65 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
$ 0.79 10.59 % $ 936 K usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 5.72 1.42 % $ 50.7 M usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 16.55 1.05 % $ 20 B australiaAustralia
MacroGenics MacroGenics
MGNX
$ 4.35 3.53 % $ 275 M usaUSA
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 13.71 0.5 % $ 1.1 B usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 100.45 0.27 % $ 5.04 B usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 1.16 0.41 % $ 123 M canadaCanada